Reversal of haemorrhagic shock in rats by tetrahydroaminoacridine
dc.contributor.buuauthor | Savcı, Vahide | |
dc.contributor.buuauthor | Çavun, Sinan | |
dc.contributor.buuauthor | Gürun, Mine Sibel | |
dc.contributor.buuauthor | Ulus, İsmail Hakkı | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Darmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAG-8716-2019 | tr_TR |
dc.contributor.researcherid | AAC-9702-2019 | tr_TR |
dc.contributor.researcherid | D-5340-2015 | tr_TR |
dc.contributor.scopusid | 6603687024 | tr_TR |
dc.contributor.scopusid | 6507468595 | tr_TR |
dc.contributor.scopusid | 55664349700 | tr_TR |
dc.contributor.scopusid | 7004271086 | tr_TR |
dc.date.accessioned | 2022-01-21T07:18:47Z | |
dc.date.available | 2022-01-21T07:18:47Z | |
dc.date.issued | 2001 | |
dc.description.abstract | The cardiovascular effects of tetrahydroaminoacridine (tacrine; THA) were investigated in haemorrhaged rats. Intracerebroventricular (i.c.v.) injection of THA (10, 25 and 50 mug) restored blood pressure in a dose- and time-dependent manner. Atropine (10 mug, i.c.v.), a muscarinic receptor antagonist, attenuated the presser response to THA (25 mug, i.c.v.), while mecamylamine (50 mug, i.c.v.), a nicotinic receptor antagonist, caused only a slight blockade in the presser effect of THA. Simultaneous pretreatment with atropine and mecamylamine almost abolished the blood pressure effect of i.c.v. THA (25 mug). Haemorrhage increased plasma levels of adrenaline, noradrenaline, vasopressin and plasma renin activity. THA (25 mug, i.c.v.) administration caused additional increases in vasopressin and adrenaline levels but not of renin activity and noradrenaline levels. The reversal of hypotension by THA was greatly attenuated by administration of either prazosin, an al-adrenoceptor antagonist (0.5 mg/kg, i.v.) or by the vasopressin V-1 receptor antagonist [beta -mercapto-beta,beta -cyclopenta-methylenepropionyl(1), O-Me-Tyr(2)-Arg(8)]-vasopressin (10 mug/kg, i.v.). Pretreatment of rats with both prazosin and the vasopressin antagonist simultaneously completely inhibited the presser response. Intravenous administration of THA (1, 1.5 and 3 mg/kg) also reversed hypotension in rats. Atropine (10 mug, i.c.v.) greatly attenuated the presser response to THA (1.5 mg/kg, i.v.), while mecamylamine (50 mug, i.c.v.) failed to change the presser effect of THA. In anaesthetised haemorrhaged rats, THA (1.5 mg/kg, i.v.) increased blood pressure and survival time of the animals. These results show that centrally and peripherally injected THA reverses haemorrhagic hypotension and increases survival time in rats. Activation of central muscarinic and nicotinic receptors is involved in the presser response to i.c.v. THA. The presser effect of i.v. THA is solely mediated by central muscarinic receptors. Moreover, the increase in plasma adrenaline and vasopressin levels appears to be involved in the presser effect of THA. | en_US |
dc.identifier.citation | Savcı, V. vd. (2001). "Reversal of haemorrhagic shock in rats by tetrahydroaminoacridine". Pharmacology, 62(1), 36-44. | en_US |
dc.identifier.endpage | 44 | tr_TR |
dc.identifier.issn | 0031-7012 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 11150921 | tr_TR |
dc.identifier.scopus | 2-s2.0-0035165180 | tr_TR |
dc.identifier.startpage | 36 | tr_TR |
dc.identifier.uri | https://doi.org/10.1159/000056070 | |
dc.identifier.uri | https://www.karger.com/Article/Abstract/56070 | |
dc.identifier.uri | http://hdl.handle.net/11452/24204 | |
dc.identifier.volume | 62 | tr_TR |
dc.identifier.wos | 000166591900007 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karger | en_US |
dc.relation.journal | Pharmacology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Haemorrhage | en_US |
dc.subject | Adrenaline | en_US |
dc.subject | Blood pressure | en_US |
dc.subject | Cholinergic receptor mechanisms | en_US |
dc.subject | Cholinesterase inhibitor | en_US |
dc.subject | Hypotension | en_US |
dc.subject | Tetrahydroaminoacridine | en_US |
dc.subject | Vasopressin | en_US |
dc.subject | Acetylcholine-release | en_US |
dc.subject | Nervous-system | en_US |
dc.subject | Blood-pressure | en_US |
dc.subject | Tacrine | en_US |
dc.subject | Choline | en_US |
dc.subject | Brain | en_US |
dc.subject | Physostigmine | en_US |
dc.subject | Invivo | en_US |
dc.subject | M(2) | en_US |
dc.subject.emtree | Prazosin | en_US |
dc.subject.emtree | Adrenalin | en_US |
dc.subject.emtree | Atropine | en_US |
dc.subject.emtree | Mecamylamine | en_US |
dc.subject.emtree | Muscarinic receptor | en_US |
dc.subject.emtree | Nicotinic receptor | en_US |
dc.subject.emtree | Noradrenalin | en_US |
dc.subject.emtree | Tacrine | en_US |
dc.subject.emtree | Noradrenalin blood level | en_US |
dc.subject.emtree | Vasopressin | en_US |
dc.subject.emtree | Vasopressin receptor antagonist | en_US |
dc.subject.emtree | Adrenalin blood level | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Pressor response | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Female hypotension | en_US |
dc.subject.emtree | Blood pressure regulation | en_US |
dc.subject.emtree | Cardiovascular effect | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Dose time effect relation | en_US |
dc.subject.emtree | Hemorrhagic shock | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Plasma renin activity | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Survival | en_US |
dc.subject.emtree | Vasopressin blood level | en_US |
dc.subject.mesh | Adrenergic alpha-antagonists | en_US |
dc.subject.mesh | Anesthetics, intravenous | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Survival analysis | en_US |
dc.subject.mesh | Cardiovascular agents | en_US |
dc.subject.mesh | Cholinesterase inhibitors | en_US |
dc.subject.mesh | Epinephrine | en_US |
dc.subject.mesh | Atropine | en_US |
dc.subject.mesh | Blood pressure | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hypotension | en_US |
dc.subject.mesh | Injections, intravenous | en_US |
dc.subject.mesh | Injections, intraventricular | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Mecamylamine | en_US |
dc.subject.mesh | Norepinephrine | en_US |
dc.subject.mesh | Prazosin | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, wistar | en_US |
dc.subject.mesh | Receptors, vasopressin | en_US |
dc.subject.mesh | Renin | en_US |
dc.subject.mesh | Shock, hemorrhagic | en_US |
dc.subject.mesh | Tacrine | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Urethane | en_US |
dc.subject.mesh | Vasopressins | en_US |
dc.subject.scopus | Citicoline; Neuroprotective Agents; Glycerylphosphorylcholine | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.title | Reversal of haemorrhagic shock in rats by tetrahydroaminoacridine | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 | en_US |